A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children

Status:	Completed
Conditions:	Infectious Disease, Pulmonary
Therapuetic Areas:	Immunology / Infectious Diseases, Pulmonary / Respiratory Diseases
Healthy:	No
Age Range:	2 - 17
Updated:	11/30/-0001
Start Date:	May 2009
End Date:	January 2014
Contact:	Pfizer CT.gov Call Center
Phone:	1-800-718-1021

A Prospective, Open-Label, Non-Randomized, Multi-Center Study To Investigate The Safety And Tolerability Of Voriconazole As Primary Therapy For Treatment Of Invasive Aspergillosis And Molds Such As Scedosporium Or Fusarium Species In Pediatric Patients

The purpose of this study is to evaluate the safety profile of voriconazole (an antifungal
drug) when used in children who have invasive aspergillosis (IA) and other rare systemic
fungal infections.

Inclusion Criteria:

- Immunocompromised with clinically compatible illness.

- Diagnosis of proven or probable or possible Invasive Aspergillosis (based on a
modified version of the revised EORTC/MSG consensus definitions).

- Diagnosis of infection due to Scedosporium or Fusarium species.

- Male and female from 2 to 17 years of age.

- Females with childbearing potential must have negative pregnancy test and be using
appropriate contraception.

Exclusion Criteria:

- Allergy or hypersensitivity to the azole drugs.

- Female subjects who are pregnant or lactating.

- Patients who received more than four days of antifungal drugs to treat the current
episode of invasive aspergillosis or rare mold infection.

- Received within 24 hours prior to enrollment drugs that may cause QT interval
prolongation.

- Significant liver, kidney or heart dysfunction.

- Not expected to survive for at least 5 days.

We found this trial at

sites

Pfizer Investigational Site

Los Angeles, California 90027

from

Los Angeles, CA